Nothing Phone (4a) Series coming to India: From date to livestream, all you need to know

JP Morgan, Morgan Stanley cut targets for Coal India, Dabur, NMDC – panic or hold?

Qualcomm to invest $150 million in Indian AI Startups, says CEO Cristiano Amon

Microsoft to invest $50 billion to bridge global AI divide, says Brad Smith

Get, Set & Go @ Zee Business BSE Bull Run! D-Street all set for fitness & financial awareness at mega marathon

Indian basmati rice gets major US boost as 5,000-tonne export deal is confirmed, farmers set to gain

India sets Guinness World Record with 2.5 lakh AI responsibility pledges

Stocks to Buy: Avinash Gorakshkar’s Top Long-Term, Positional and Short-Term Picks

1:2 Bonus Issue, 1:2 Stock Split: 1000 shares will turn into 3000—Do you own?

India AI Summit 2026: World leaders urge AI governance and responsible use

While markets continued their rally, things were different for big bull Rakesh Jhunjhunwala as few of his holdings were trading on a negative note. In fact, Jhunjhunwala’s one pharma stock witnessed hefty selling pressure and plunged by nearly 7% in one day. Jubilant Life Science was worst performer on Wednesday’s trading session in Jhunjhunwala’s portfolio. Interestingly, the ace investor had increased his holding in the same company by another 0.31% during Q3FY19 period. This brings in the question to whether one should buy Jubilant share price. 
At around 1205 hours, Jubilant share price was trading at Rs 794.20 per piece down by Rs 49.15 or 5.83% on BSE. However, the stock has also touched an intraday low of Rs 786 per piece, resulting in overall tumble of 7% on the index. Hence, making many investors poorer including Jhunjhunwala in intraday session. 
In Jubilant, Jhunjhunwala now holds about 1.88% stake with 3,000,000 equity shares which are worth Rs 252 crore currently. 
<h2>Should you buy Jubilant Life Science? </h2>
Surajit Pal analysts at Prabhudas Lilladher said, “We cut our earnings estimates by 2.2% and 3.9% in FY20E and FY21E respectively, following assumptions of lower sales growth in US formulation. We expect that negative impact of the event as well as raising new debt capital will result in compression of PE multiples. We reduce assigned EV/EBTIDA to 7.5x (from 8.5x) on FY21E in our SOTP valuations of the company.”
Pal adds, “The current valuation reflects all possible positive developments in the near to medium term. With muted demand offtake in chemical biz (LSI), higher leverage and regulatory uncertainties, we downgrade our recommendation to ‘Reduce’ and lower TP to Rs703 (Rs822 earlier).’
<blockquote data-lang="en"><a href="https://twitter.com/hashtag/ResearchGurukul?src=hash&amp;ref_src=twsrc%5Etfw">#ResearchGurukul</a> | समझिए सीमेंट कंपनियों की काॅस्ट स्ट्रक्चरिंग पैंटोमैथ AMC के फंड मैनेजर वरिंदर बंसल से अनिल सिंघवी के साथ।
पूरा कार्यक्रम देखें: <a href="https://t.co/fBR9oSzdOS">https://t.co/fBR9oSzdOS</a><a href="https://twitter.com/AnilSinghviZEE?ref_src=twsrc%5Etfw">@AnilSinghviZEE</a> <a href="https://twitter.com/varinder_bansal?ref_src=twsrc%5Etfw">@varinder_bansal</a> <a href="https://t.co/HYTf5Vnauj">pic.twitter.com/HYTf5Vnauj</a>
— Zee Business (@ZeeBusiness) <a href="https://twitter.com/ZeeBusiness/status/1108274239994499072?ref_src=twsrc%5Etfw">March 20, 2019</a></blockquote>
<script async="" src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
With this, it can be said that Jubilant share price is set to tumble ahead. However, considering Jhunjhunwala sees longer term picture and his holdings are massive in Jubilant, it would be keenly watched to his action in this stock in last quarter period of FY19.

While markets continued their rally, things were different for big bull Rakesh Jhunjhunwala as few of his holdings were trading on a negative note. In fact, Jhunjhunwala’s one pharma stock witnessed hefty selling pressure and plunged by nearly 7% in one day. Jubilant Life Science was worst performer on Wednesday’s trading session in Jhunjhunwala’s portfolio. Interestingly, the ace investor had increased his holding in the same company by another 0.31% during Q3FY19 period. This brings in the question to whether one should buy Jubilant share price. At around 1205 hours, Jubilant share price was trading at Rs 794.20 per piece down by Rs 49.15 or 5.83% on BSE. However, the stock has also touched an intraday low of Rs 786 per piece, resulting in overall tumble of 7% on the index. Hence, making many investors poorer including Jhunjhunwala in intraday session. In Jubilant, Jhunjhunwala now holds about 1.88% stake with 3,000,000 equity shares which are worth Rs 252 crore currently. Should you buy Jubilant Life Science? Surajit Pal analysts at Prabhudas Lilladher said, “We cut our earnings estimates by 2.2% and 3.9% in FY20E and FY21E respectively, following assumptions of lower sales growth in US formulation. We expect that negative impact of the event as well as raising new debt capital will result in compression of PE multiples. We reduce assigned EV/EBTIDA to 7.5x (from 8.5x) on FY21E in our SOTP valuations of the company.”Pal adds, “The current valuation reflects all possible positive developments in the near to medium term. With muted demand offtake in chemical biz (LSI), higher leverage and regulatory uncertainties, we downgrade our recommendation to ‘Reduce’ and lower TP to Rs703 (Rs822 earlier).’#ResearchGurukul | समझिए सीमेंट कंपनियों की काॅस्ट स्ट्रक्चरिंग पैंटोमैथ AMC के फंड मैनेजर वरिंदर बंसल से अनिल सिंघवी के साथ।पूरा कार्यक्रम देखें: https://t.co/fBR9oSzdOS@AnilSinghviZEE @varinder_bansal pic.twitter.com/HYTf5Vnauj— Zee Business (@ZeeBusiness) March 20, 2019With this, it can be said that Jubilant share price is set to tumble ahead. However, considering Jhunjhunwala sees longer term picture and his holdings are massive in Jubilant, it would be keenly watched to his action in this stock in last quarter period of FY19. 

Interestingly, the ace investor had increased his holding in the same company by another 0.31% during Q3FY19 period. This brings in the question to whether one should buy Jubilant share price.  

This pharma stock owned by Rakesh Jhunjhunwala plunges 7 per cent: Buying opportunity or not? 

news-this-pharma-stock-owned-by-rakesh-jhunjhunwala-plunges-7-per-cent-buying-opportunity-or-not-90876

While markets continued their rally, things were different for big bull Rakesh Jhunjhunwala as few of his holdings were trading on a negative note. In fact, Jhunjhunwala’s one pharma stock witnessed hefty selling pressure and plunged by nearly 7% in one day. Jubilant Life Science was worst performer on Wednesday’s trading session in Jhunjhunwala’s portfolio. Interestingly, the ace investor had increased his holding in the same company by another 0.31% during Q3FY19 period. This brings in the question to whether one should buy Jubilant share price.  At around 1205 hours, Jubilant share price was trading at Rs 794.20 per piece down by Rs 49.15 or 5.83% on BSE. However, the stock has also touched an intraday low of Rs 786 per piece, resulting in overall tumble of 7% on the index. Hence, making many investors poorer including Jhunjhunwala in intraday session.  In Jubilant, Jhunjhunwala now holds about 1.88% stake with 3,000,000 equity shares which are worth Rs 252 crore currently.  Should you buy Jubilant Life Science?  Surajit Pal analysts at Prabhudas Lilladher said, “We cut our earnings estimates by 2.2% and 3.9% in FY20E and FY21E respectively, following assumptions of lower sales growth in US formulation. We expect that negative impact of the event as well as raising new debt capital will result in compression of PE multiples. We reduce assigned EV/EBTIDA to 7.5x (from 8.5x) on FY21E in our SOTP valuations of the company.” Pal adds, “The current valuation reflects all possible positive developments in the near to medium term. With muted demand offtake in chemical biz (LSI), higher leverage and regulatory uncertainties, we downgrade our recommendation to ‘Reduce’ and lower TP to Rs703 (Rs822 earlier).’ #ResearchGurukul | समझिए सीमेंट कंपनियों की काॅस्ट स्ट्रक्चरिंग पैंटोमैथ AMC के फंड मैनेजर वरिंदर बंसल से अनिल सिंघवी के साथ। पूरा कार्यक्रम देखें: https://t.co/fBR9oSzdOS@AnilSinghviZEE @varinder_bansal pic.twitter.com/HYTf5Vnauj — Zee Business (@ZeeBusiness) March 20, 2019 With this, it can be said that Jubilant share price is set to tumble ahead. However, considering Jhunjhunwala sees longer term picture and his holdings are massive in Jubilant, it would be keenly watched to his action in this stock in last quarter period of FY19.  